Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Oncogene ; 30(6): 642-53, 2011 Feb 10.
Article in English | MEDLINE | ID: mdl-20956946

ABSTRACT

Milk fat globule-epidermal growth factor-factor VIII (MFGE8), also called lactadherin or SED1, is a secreted integrin-binding protein that promotes elimination of apoptotic cells by phagocytes leading to tolerogenic immune responses, and vascular endothelial growth factor (VEGF)-induced angiogenesis: two important processes for cancer development. Here, by transcriptomic analysis of 228 biopsies of bladder carcinomas, we observed overexpression of MFGE8 during tumor development, correlated with expression of genes involved in cell adhesion or migration and in immune responses, but not in VEGF-mediated angiogenesis. To test whether MFGE8 expression was instrumental in bladder tumor development, or a simple consequence of this development, we used genetic ablation in a mouse model of carcinogen-induced bladder carcinoma. We showed that Mfge8 was also upregulated in mouse carcinoma, and that in its absence, Mfge8-deficient animals developed less advanced tumors. Angiogenesis was similar in carcinogen-treated Mfge8-expressing or -deficient bladders, thus ruling out a major role of the proangiogenic function of Mfge8 for its protumoral role. By contrast, the tumor-promoting role of Mfge8 was not observed anymore in mice devoid of adaptive immune system, and human tumors overexpressing MFGE8 where invaded with macrophages and regulatory T cells, thus suggesting that MFGE8/lactadherin favors development of bladder tumors at least partly by an immune system-dependent mechanism. Our observations suggest future use of MFGE8-inhibiting molecules as therapies of bladder carcinomas, and of a limited number of other human cancers, in which our analysis of public databases also revealed overexpression of MFGE8.


Subject(s)
Antigens, Surface/metabolism , Carcinogens/metabolism , Carcinoma/metabolism , Milk Proteins/metabolism , Urinary Bladder Neoplasms/metabolism , Animals , Antigens, Surface/genetics , Antigens, Surface/immunology , Butylhydroxybutylnitrosamine/administration & dosage , Carcinoma/chemically induced , Carcinoma/immunology , Carcinoma/pathology , Cell Adhesion/immunology , Cell Transformation, Neoplastic , Gene Expression Profiling , Humans , Macrophages/immunology , Male , Mice , Mice, Inbred C57BL , Milk Proteins/genetics , Milk Proteins/immunology , Neovascularization, Pathologic/metabolism , T-Lymphocytes, Regulatory/immunology , Urinary Bladder Neoplasms/chemically induced , Urinary Bladder Neoplasms/immunology , Urinary Bladder Neoplasms/pathology
2.
J Biol Chem ; 276(15): 12228-34, 2001 Apr 13.
Article in English | MEDLINE | ID: mdl-11150308

ABSTRACT

Heparin affin regulatory peptide (HARP) is a 18-kDa heparin-binding polypeptide that is highly expressed in developing tissues and in several primary human tumors. It seems to play a key role in cellular growth and differentiation. In vitro, HARP displays mitogenic, angiogenic, and neurite outgrowth activities. It is a secreted protein that is organized in two beta-sheet domains, each domain containing a cluster of basic residues. To assess determinants involved in the biological activities of HARP, C-terminally truncated proteins were produced in Chinese hamster ovary-K1 cells and tested for their mitogenic, tumor formation in nude mice and neurite outgrowth activities. Our data clearly indicate that the residues 111-136 of the lysine-rich C-terminal domain are involved in the mitogenic and tumor formation activities of HARP. Correlatively, no signal transduction was detected using the corresponding mutant, suggesting the absence of HARP binding to its high affinity receptor. However, this C-terminal domain of HARP is not involved in the neurite outgrowth activity. We also demonstrate that HARP signal peptide cleavage could led to two maturated forms that are both but differentially mitogenic.


Subject(s)
Carcinogens/pharmacology , Carrier Proteins/physiology , Cytokines/physiology , Mitogens/physiology , 3T3 Cells , Animals , CHO Cells , Carrier Proteins/chemistry , Carrier Proteins/genetics , Cricetinae , Cytokines/chemistry , Cytokines/genetics , Female , Humans , Mice , Mice, Nude , Recombinant Proteins/genetics , Recombinant Proteins/metabolism
3.
Biochem Biophys Res Commun ; 266(2): 437-42, 1999 Dec 20.
Article in English | MEDLINE | ID: mdl-10600521

ABSTRACT

Heparin affin regulatory peptide (HARP), also called pleiotrophin (PTN), is a secreted polypeptide which binds to heparin and plays a key role in cellular growth and differentiation. In order to assess the determinants potentially important to its biological activity, we tested the ability of HARP to oligomerize, a process involved in mitogenic activity of the heparin-binding fibroblast growth factor. Using dissuccinimidyl suberate cross-linking experiments and affinity chromatography, we report that human HARP forms noncovalent dimers. Dimerization is dependent on the presence of heparin or other sulfated glycosaminoglycans, as chlorate treatment of cells inhibits this process. In vitro, different glycosaminoglycans, such as dermatan sulfate and chondroitin sulfate-C, also induce a dimer assembly of HARP. The relevance of this process was supported by experiments demonstrating that HARP is secreted as a dimer in conditioned medium of NIH-3T3 cells that overexpressed this growth factor and is also associated to the cell surface or to the extracellular matrix.


Subject(s)
Carrier Proteins/chemistry , Cytokines/chemistry , Glycosaminoglycans/chemistry , 3T3 Cells , Animals , Chlorates/chemistry , Chondroitin Sulfates/chemistry , Cross-Linking Reagents/chemistry , Dermatan Sulfate/chemistry , Dimerization , Heparin/chemistry , Humans , Immunoblotting , Mice , Succinimides/chemistry , Transfection
SELECTION OF CITATIONS
SEARCH DETAIL
...